press & news
Press Releases
NECTID ANNOUNCES INITIATION OF THE DEVELOPMENT OF ITS FXR PLATFORM- NFX-21 FOR NONALCOHOLIC FATTY LIVER DISEASE (NALFD). Princeton, NJ – February 18, 2014
Nectid, Inc. (www.nectid.com), a Princeton based pharmaceutical product development company focused on discovering and developing novel platform technologies, announced initiating clinical development of FXR Platform for Non-Alcoholic Fatty Liver Disease indication in the United States.
Nectid Announces launch of stable omega fortified Whey Protein platform. Princeton, NJ – January 31, 2014
Nectid, Inc. (www.nectid.com), a Princeton based privately pharmaceutical and nutritional technology development company focused on discovering and developing nutritional products and novel drugs, announced the launch of proprietary and patent pending omega-3 fortified Whey Protein platform for the food and nutrition industry.
NECTID ANNOUNCES INITIATION OF CLINICAL DEVELOPMENT OF AUTISM AND PAIN DRUGS. Princeton, New Jersey – August 16, 2012
Nectid, Inc. (www.nectid.com), a Princeton based pharmaceutical product development company focused on discovering and developing novel drugs, announced initiating clinical development of agomelatine for autism and pain indications in the United States.
NECTID ANNOUNCES SERIES A FINANCING FROM A SINGAPORE VENTURE FIRM. Princeton, New Jersey – April 15, 2012
Nectid, Inc. (www.nectid.com), a Princeton based pharmaceutical product development company focused on discovering and developing novel drugs, announced successful closing of a Series A financing from Agnus Global Partners, a Singapore based venture firm.
Grunenthal group acquires pain patent portfolio from NECTID Inc. Princeton, New Jersey – March 9, 2011
Nectid, Inc. (www.nectid.com), announced today that it has completed the sale of a number of patents and patents-applications to Grunenthal GmbH (www.grunenthal.com), an European specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes a number of novel chemical entities from Nectid’s Pain Drug Discovery program and two key drug delivery platforms.
NECTID announces sale of certain drug delivery patents. Princeton, New Jersey – April 26, 2010
Nectid, Inc. (www.nectid.com), a Princeton based pharmaceutical product development company focused on developing innovative drug delivery technologies, announced the sale of its portfolio of patents to Pro-Tect Inc, a West Caldwell , NJ based pharmaceutical company, traded under ticker symbol PRTT. Nectid’s founder Ram Sesha said, “This acquisition is a testimony to Nectid’s developmental capabilities and will enable Nectid to commercialize these important intellectual properties using Pro-Tect’s access to capital markets".